Arix Bioscience plc
Arix Bioscience plc is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Arix Bioscience plc.
Arix Bioscience plc is a company.
Key people at Arix Bioscience plc.
Arix Bioscience plc is a London-based global venture capital firm specializing in biotechnology and life sciences investments. Founded to invest in and build breakthrough biotech companies leveraging cutting-edge advances, it provides capital, expertise, and networks to entrepreneurs developing treatments for patients[1][2][3]. Its mission centers on accelerating life sciences innovations while offering listed company access to broader investors; key sectors include biotechnology, healthcare, and preclinical/clinical-stage assets across all growth stages[1][2][5]. With only 9 employees, it has influenced the startup ecosystem through targeted investments, though it is now in liquidation, limiting ongoing impact[2][5][6].
Arix Bioscience plc was incorporated on 15 September 2015 as Perceptive Bioscience Investments Limited, rebranded to Arix Bioscience Limited in April 2016, and became a public limited company shortly after[6]. Originally known as Perceptive Bioscience, it emerged as a venture capital entity focused on biotech, backed by investors like RTW Biotech Opportunities, Woodford Investment Management, Takeda Ventures, UCB, and Chris Evans[4]. Key figures include board members such as Chair Peregrine Moncreiffe, Senior Independent Director Dr. Debra Barker (with 25+ years in pharma at Roche, Novartis, etc.), and others like Tom Davidson; the firm evolved from private roots to a listed entity (ARIX:LN) on Vox Markets, emphasizing global life sciences sourcing and development[1][2][6]. Early traction involved building a portfolio in high-potential biotech, but by 2025, it entered liquidation with overdue accounts as of December 2023[5][6].
Arix Bioscience rode the biotech boom in life sciences, capitalizing on advances in treatments for infectious diseases, oncology, immunology, and transplantation amid rising demand for innovative therapies[1]. Timing aligned with post-2015 VC growth in publicly accessible biotech investing, influencing the ecosystem by funding startups, boosting research, and creating jobs—e.g., via funds like Wales' £50m life sciences initiative that met objectives in finance access and sector growth despite fee concerns[4]. Market forces favoring it included global pharma needs and investor interest in high-impact biotech, though liquidation reflects challenges like portfolio concentration and market shifts, reducing its active ecosystem role[4][5][6].
In liquidation since at least 2025, with overdue 2023 accounts and confirmation statements, Arix Bioscience is winding down operations, likely realizing remaining assets from its biotech portfolio via sales or distributions[5][6]. Trends like AI-driven drug discovery and personalized medicine may shape any successor entities or investor redeployments, but its influence as a listed VC pioneer in life sciences appears concluded. This ties back to its core as a bridge for public investment in biotech breakthroughs—now shifting focus to acquirers or new vehicles carrying forward its seeded innovations[1][4].
Key people at Arix Bioscience plc.
